Platelet-activating factor (PAF) desensitizes as well as stimulates its various target cells, We find that human polymorphonuclear neutrophils (PMN) exposed to PAF became maximally unresponsive to a second PAF challenge within 15-90 s in assays of Ca2+ mobilization and degranulation. The cells regained full PAF-sensitivity over the ensuing 20-40 min. These effects correlated with changes in PAF receptor availability. PMN treated with PAF, washed in regular buffer and assayed for PAF binding exhibited falls (maximal in 15 s), followed by rises (reaching control levels by 60 min), in the number of high-affinity PAF receptors. However, tracking studies showed that [3H]PAF accumulated on the cell surface for -2 min before being internalized. Regular-buffer washes did not remove this superficial PAF, whereas a washing regimen using excess albumin to adsorb PAF removed 99 % of the surface compound. PMN washed by the latter regimen after PAF exposure lost PAF receptors relatively slowly (maximal at -5 min), but the ultimate extent of this loss and the rate at which receptor expression normalized were similar to those of cells washed in regular buffer. Neither cycloheximide nor actinomycin D influenced the course of the receptor changes, but two protein kinase C (PKC) blockers, staurosporine and 1-(5-isoquinolinesulphonyl)piperazine, inhibited the receptor-receptor-depleting actions of PAF. Indeed, a phorbol diester activator of PKC also caused PMN to decrease high-affinity PAF receptor numbers, and the two PKC blockers antagonized this action at concentrations that inhibited PAF-induced PAF receptor losses. We conclude that: (a) PAF induces PMN to down-regulate and then to re-express PAF receptors independently of protein synthesis; (b) these changes are likely to underlie the later stages and reversal of desensitization; (c) the onset (t < 2 min) of desensitization, however, precedes receptor down-regulation and must be due to receptor uncoupling from transductional elements; and (d) down-regulation of receptors for PAF appears to be mediated by PKC and/or elements inhibited by PKC blockers.
INTRODUCTION
The pluripotent autocoid platelet-activating factor (PAF) operates through plasma-membrane receptors to initiate a standard transductional mechanism. It stimulates cells to activate Gproteins, hydrolyse endogenous lipids, raise [Ca2+] , and mobilize key effector enzymes such as PKC. As consequences of these events, the cells respond functionally and then pass through a temporary state of PAF insensitivity [1] [2] [3] . The same cells also internalize PAF (1-O-alkyl-2-acetyl-GPC), serially convert it into sn-2-lyso and acylated metabolites, and store the final 1-0-alkyl-2-acyl-GPC product in Golgi and/or granules [4] [5] [6] . Like other similarly acting agonists, then, PAF may bind its plasmalemmal receptors to become endocytosed in vesicles that uncouple ligands from receptors, transport ligand to digestive organelles, and cycle receptors back to the cell surface [7] . In effect, this pathway shuttles receptors off and on the plasmalemma to depress and restore ligand sensitivity while clearing the microenvironment of stimulus. As a hydrophobic phospholipid, however, PAF preferentially solvates in membranes [8, 9] . It will move spontaneously from carrier albumin to, e.g., red blood cells. At first, such movements are fully reversible. For example, addition of excess of albumin removes this PAF from the erythrocytes. Over time, however, red-cell PAF internalizes, thereby becoming resistant to albumin extraction [10, 11] . PAF likewise enters rabbit platelets, guinea-pig PMN and rat Kupffer cells by BSA- extractable and -unextractable steps. The latter cells, unlike erythrocytes, have PAF receptors as well as PAF metabolizing activity. Nevertheless, their ability to process PAF is only moderately and indirectly blocked by PAF-receptor antagonists [12] [13] [14] . Moreover, HL-60 promyelocytes lack PAF receptors, yet metabolize the ligand even more rapidly than do their mature PAF-receptor-bearing counterparts, human PMN [15, 16] . Human PMN, indeed, can be clipped of PAF receptors by Pronase without altering their ability to metabolize PAF [15] . PAF processing therefore more closely resembles the receptorindependent processing of exogenous lysophospholipids [17] than the receptor-mediated endocytotic processing of hydrophillic peptides [18] . The following model has evolved [6, [10] [11] [12] [13] [14] [15] . Thermodynamic forces drive PAF from BSA to the outer leaf of the plasma membrane. At this site, PAF can return to BSA, bind with its plasma-membrane receptors, or ffip internally to sequester from extracellular BSA and, depending on the availability of degradative enzymes, become metabolized.
The peculiarities of PAF processing complicate receptor analysis during desensitization. Rat Kupffer cells, when incubated with PAF and then buffer-washed, show decreased ability to bind PAF. The effect develops within 4 min, reverses only when PAF is removed from the culture media and new protein synthesis is allowed to occur (i.e. cycloheximide inhibits it), and generally persists through serial BSA extractions. Cells exposed to PAF for short periods (e.g. < 4 min), however, bind PAF normally after Abbreviations used: PMN, polymorphonuclear neutrophils; GPC, sn-glycero-3-phosphocholine; PAF, platelet-activating factor (1-0-hexadecyl-2-acetyl-GPC); [3HIPAF, 1-0-[9,10-3H2]hexadecyl-2-acetyl-GPC; PKC, protein kinase C; PMA, phorbol 12-myristate 13- were mixed with I ml of buffer and 1.6 ml of methanol/ chloroform (1:1, v/v). After isolation of chloroform layers, methanol/water layers were mixed with 2 x 0.8 ml ofchloroform. Pooled chloroform layers were dried under a stream of N2, applied to pre-activated (180°C, 3 h) silica-gel G t.i.c. plates, and developed to 15 cm with chloroform/methanol/acetic acid/water (50 :25: 8:.4, by vol.). Sections (5 mm) of these plates were assayed for radioactivity and identified as co-migrating with PAF, lyso-PAF and diacyl-GPC standards [6] . PAF [10] [11] [12] [13] [14] . We improved these results, using a pH 9.3 buffer plus 50 g of BSA/100 ml and 10 nM-EDTA. Efficacy was determined by incubating 107 PMN in 1 (Fig. 4, and 9% (Fig. 4, right panels) . T.l.c. analyses determined the nature of the released radiolabel. 3H in the extracellular fluid from all initial incubation (4 and 37°C) or in PMN incubated with [3H]PAF at 4°C co-migrated (> 95 %) with PAF (results not shown). Label (> 95 % recovery) in PMN exposed at 37 "C to 32 pM-[3H]PAF or 1 OOpM-[3H]PAF+9.9 nM-PAF and then washed in buffer contained species co-migrating with PAF and diacyl-GPC. Material co-migrating with PAF reached a peak at 2.5 min and declined thereafter, whereas material co-migrating with diacyl-GPC progressively accumulated (Fig. 5, left panels) . BSA extraction released 50-80 % of the PAF-co-migrating label that bound to PMN during the initial 0.5-2.5 min of incubation. It released only 20-40 % ofPAF label from 5-20 min incubations and never had significant effects on the diacyl-GPC-co-migrating compound (Fig. 5, right panels) (Table 1) compared with unstimulated cells. The effect began more slowly than that in buffer-washed PMN (Fig. 6) (Fig. 2) , degranulation ceases at -30 s [23] , and PKC mobilization reverses after 120 s [24] . At these times, PAF remains mostly outside the PMN (Fig. 4, right panels) , and the extracellular fluid of PMN suspensions treated with 100 nM-PAF for 3 min is fully capable of stimulating fresh PMN [25] . (Fig. 2) , and at the first time tested, 1.5 min, in degranulation assays (Fig. 1) (Fig. 3, lower panel) and high-affinity receptors (Table 1) . Previous studies have demonstrated these findings, but did not consider that some of the desensitizing dose of PAF may adhere with PMN to contaminate subsequent binding assays [15, 26] . Standard BSA extraction methods release 80-90% of this contamination [10] [11] [12] [13] [14] . We used a buffer containing very high BSA concentrations (50 mg/100 ml), 10 mM-EDTA, and alkaline pH (9.3) to release 99 % of the PAF taken up by PMN at 4 'C. This washing regimen therefore stripped PMN of virtually all PAF that associated with high-affinity receptors, low-affinity receptors and non-specific adsorption sites. Never- theless, BSA extractions were very much less effective in releasing PAF bound to PMN at 37°C (Fig. 4) . At 37°C, PAF initially accumulated in PMN in a BSA-extractable form. Within 2.5 min, however, it was converted progressively into a BSA-unextractable form and then rapidly accumulated as acylated metabolite (Fig.  5) . Hence, PMN incubated with PAF at 37°C for < 2.5 min and then buffer-washed retain significant amounts of intact PAF in a superficial (i.e. BSA-extractable) site. This contamination probably contributed to the loss of [3H]PAF specific binding capacity and high-affinity PAF receptors observed in PMN that were buffer-washed after exposure to PAF for < 2.5 min; it cannot explain later-developing changes in PAF binding. At 37 OC, then, PAF acts relatively slowly to decrease the availability of, or down-regulate, its high-affinity receptors. These receptors may have assumed a low-affinity configuration, formed a nondissociating complex with PAF, been internalized, or been shed from the cell. Although our experiments do not discriminate among these possibilities, we note that desensitized PMN soon regained PAF receptors (Table 1) even when pretreated with cycloheximide or actinomycin D. Hence, the PAF receptor changes observed here are unlikely to be due to irreversible processes (such as receptor shedding) that are followed by a compensatory expression of newly synthesized receptors.
Homma et al. [12] found that PAF did not alter rabbit platelet PAF receptors, whereas Chao et al. [14] reported that PAF caused a true (i.e. resistant to BSA extraction) down-regulation of its Kupffer-cell receptors. The latter effect endured for hours and required protein synthesis for reversal. PMN responses to PAF had some characteristics of both these cell types. Like Kupffer cells, PMN exposed to PAF down-regulated their highaffinity PAF receptors. This occurred in PMN that were BSAextracted between desensitization and binding assays (Fig. 6 Fig. 6 ) and PAF insensitivity (t, < 15 s, Figs. I and 2, and the upper panel of Fig. 3 ). PMN desensitization that developed shortly after PAF challenge must therefore reflect an uncoupling of PAF receptors from transducer elements similar to that occurring in rabbit platelets [12] . Additionally, PMN regained PAF sensitivity (t1 10-20 min) more quickly than [3H]PAF specific binding (t' "_ 40 min). We note that PAF enhances PMN responses to diverse stimuli [27] [28] [29] , including fMLP (Fig. 1, right panels) . Since priming may reflect the excitation of post-receptor events [30] [33, 34] . These data suggest that PKC may mediate not only the stimulating, but also the receptor-down-regulating, actions of PAF. Our studies add support to this notion. Two PKC blockers, staurosporine and CI, inhibited the effects of PAF on its receptors (Figs. 7 and 8, Table 1 ). Both drugs acted at concentrations paralleling their respective potencies in inhibiting PMA-induced 02-production and PMA-induced decreases in [3H]PAF specific binding (Fig. 9) . Moreover, recent studies provide evidence implicating PKC in the bioactions of PAF on diverse cell types [35] [36] [37] [38] [39] . The data, when taken together, suggest that PKC has a general role in down-regulating PAF receptors. By analogy with other systems [40, 41] , the phosphorylating enzyme may achieve this effect by acting directly on PAF receptors or on systems that support PAF receptors (e.g. G-proteins). Since PKC blockers show nonselective inhibitory effects [42, 43] , however, our results seem best interpreted conservatively: they implicate a staurosporine-and CI-sensitive element in PAF-induced receptor down-regulation, but further studies are needed to define this element's identity and its role, if any, in PAF-desensitization responses exhibited by other cell types.
In conclusion, our studies afford an alternative model for PAF desensitization that may be generally applicable to cells which, when exposed to PAF, mobilize PKC and pass through a brief period of PAF-insensitivity. The model divides desensitization into three stages. Stage I involves almost immediate losses in PAF-sensitivity that are not accompanied by comparable changes in PAF receptors. These receptors must have uncoupled from transductional elements while retaining their PAF-binding capacity. PMN stage I occurs for 1-22 min after challenge. Stage II cells continue in a maximally desensitized state and have maximally down-regulated their high-affinity PAF receptors. PKC or an element inhibited by PKC blockers may mediate receptor down-regulation. PMN stage II begins by -1.25-2.5 min and ends after -5-10 min of PAF exposure. During this stage, PMN also became primed, as indicated by their hypersensitivity to fMLP. In stage III, cells recover PAFsensitivity and regain high-affinity PAF receptors. Although receptor recovery is essential for reversing desensitization, an underlying non-selective state of priming may explain imbalances between PAF-sensitivity and a slower recovery of PAF receptors. PMN stage III proceeds for -40 min and may reflect the recycling of previously expressed receptors, receptor interconversions between low-and high-affinity states, and/or the uncovering of cryptic receptors. It does not involve any appreciable synthesis of new receptors. As the three stages proceed, cells internalize PAF relying principally on a direct pathway rather than a receptor-mediated endocytotic route. In stage I, PAF accumulates mostly in BSA-extractable superficial sites, such as on plasma-membrane receptors and in the outer leaflet of the plasmalemma. This PAF interferes with standard PAF-binding assays. However, surface-attached PAF quickly flips internally and thereafter becomes progressively metabolized to its acylated bio-inactive storage product. PAF is thereby cleared from the environment around newly expressed PAF 
